NDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
6/8 — Strong
COMBIGAN (brimonidine tartrate, timolol maleate) by AbbVie is components: brimonidine tartrate and timolol. Approved for elevated intraocular pressure (iop) in patients with glaucoma, ocular hypertension, replacement therapy due to inadequately controlled iop and 2 more indications. First approved in 2007.
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIGAN is a fixed-dose combination ophthalmic solution containing brimonidine tartrate (alpha-2 adrenergic agonist) and timolol maleate (non-selective beta-blocker) for topical ocular use. It reduces elevated intraocular pressure (IOP) through dual mechanisms: brimonidine decreases aqueous humor production and increases uveoscleral outflow, while timolol inhibits beta-adrenergic receptors. It is indicated for glaucoma and ocular hypertension in patients whose IOP is inadequately controlled on monotherapy.
$0.232BPart D
LOE ApproachingProduct is approaching loss of exclusivity with $232M in annual Part D spending, signaling mid-to-late stage brand team focused on generic defense and lifecycle extension strategies.
Mechanism of Action
components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher…
Worked on COMBIGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.